BTK and pancreatic neoplasm: A randomized phase II clinical trial (NCT02362048) reported that the combination of BTK inhibitor acalabrutinib and pembrolizumab led to reduction of reductions in granulocytic (CD15+) MDSCs in peripheral blood of patient with pancreatic cancer, but the overall response rate and disease control rate were disappointing (132).